Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6001 add-on to triple therapy in COPD with chronic bronchitis
2020-003666-40Phase 3Active
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanimilast in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Annual rate of moderate and severe exacerbations over 52 weeks. Started Feb 2021; status: active.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on 2020-003666-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003666-40.